Drugs / RC148
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06883630 | Mar 2025 → Aug 2026 overdue | non-small cell lung carcinoma | RemeGen Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06016062 | Sep 2023 → Dec 2025 overdue | cancer | RemeGen Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06038396 | Aug 2023 → Feb 2026 overdue | neoplasm | RemeGen Co., Ltd. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06642545 | Feb 2025 → Oct 2026 expected | breast cancer | RemeGen Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07462143 | May 2026 → May 2027 expected | colorectal cancer | RemeGen Co., Ltd. | Recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07829549 | Sep 2026 → Apr 2031 expected | — | RemeGen Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07416474 | Apr 2026 → Dec 2027 expected | non-small cell lung carcinoma | RemeGen Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-09-15 | RemeGen Co., Ltd. | Results 2026WCLC | Favorable Phase 1b Data on RC148 (ABBV-1480) as 1L Therapy for Squamous and Non-Squamous NSCLC Presented, with Phase III Protocol Unveiled remegen.com ↗ |
| 2026-01-16 | RemeGen Co., Ltd. | Regulatory 2026 JPM | Rongchang Biotech: Delivering Innovation at Scale, Solidifying Its Global Competitive Edge for the Future remegen.com ↗
The Phase III clinical trial of RC148 combined with chemotherapy as first-line treatment for squamous non-small cell lung cancer (NSCLC) has been approved by the CDE (Center for Drug Evaluation). |
| 2025-08-08 | RemeGen Co., Ltd. | Regulatory RemeGen's Independently-Developed Bispecific Antibody RC148 Approved to Proceed Phase II Clinical Trial in US by FDA remegen.com ↗
The clearance of IND application by the FDA is a significant milestone for RC148 which should expedite its global development process. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-09-15 | RemeGen Co., Ltd. | 2026WCLC | Favorable Phase 1b Data on RC148 (ABBV-1480) as 1L Therapy for Squamous and Non-Squamous NSCLC Presented, with Phase III Protocol Unveiled remegen.com ↗ |
| 2026-06-15 | RemeGen Co., Ltd. | First Patient In Achieved in RemeGen’s Phase II/III Clinical Study of RC148 in Combination with Chemotherapy as First-Line Therapy for Unresectable or Metastatic Colorectal Cancer remegen.com ↗ |
| 2026-01-16 | RemeGen Co., Ltd. | 2026 JPM | Rongchang Biotech: Delivering Innovation at Scale, Solidifying Its Global Competitive Edge for the Future remegen.com ↗ |
| 2026-01-12 | RemeGen Co., Ltd. | Remegen and AbbVie sign exclusive licensing agreement for RC148 remegen.com ↗ |
| 2025-08-08 | RemeGen Co., Ltd. | RemeGen's Independently-Developed Bispecific Antibody RC148 Approved to Proceed Phase II Clinical Trial in US by FDA remegen.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RC148 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06883630 ↗ |
| Route | Intravenous | “RC148 injection will be administered as an intravenous (IV) infusion” NCT06016062 ↗ |